Director, Neuroscience External Innovation
Gabriele joined Takeda Pharmaceuticals in 2013. She is focusing on cell and gene therapy approaches.
Gabriele Proetzel has earned a Master in Life Sciences from the Ludwig-Maximilian University of Würzburg, Germany, with the Master thesis prepared at the Max Planck Institute of Immunology, Freiburg, Germany. She received her Ph.D. from the University of Cincinnati, Ohio, USA with her thesis work about knockout mouse models via targeted mutagenesis in ES cells in the laboratory of Prof. Thomas Doetschman. She completed her postdoctoral training at the Max Planck Institute for Biophysical Chemistry under the supervision of Prof. Peter Gruss in Göttingen, Germany.
Following her postdoctoral training, Gabriele became a group leader in the cell biology and musculoskeletal group at Boehringer Mannheim/Roche Penzberg, Germany. Then she joined the startup Deltagen Inc., San Carlos, CA, where she was critical for building the mouse model pipeline. In 2001, Gabriele accepted the position as Chief Scientific Officer at the biotech startup Scil Proteins, Halle Germany, and was responsible for R&D in protein therapeutics including alternative scaffold proteins, as well as intellectual property and licensing activities. Before joining Takeda, Gabriele held the position of Associate Director of Technology Transfer at the non-profit research institution The Jackson Laboratory in Bar Harbor, Maine, USA